<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9935699</article-id><article-id pub-id-type="pmcid-ver">PMC9935699.1</article-id><article-id pub-id-type="pmcaid">9935699</article-id><article-id pub-id-type="pmcaiid">9935699</article-id><article-id pub-id-type="pmid">36817419</article-id><article-id pub-id-type="doi">10.3389/fimmu.2023.1131057</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Precision-engineering of subunit vaccine particles for prevention of infectious diseases</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Chen</surname><given-names initials="S">Shuxiong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/910828"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pounraj</surname><given-names initials="S">Saranya</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2079882"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sivakumaran</surname><given-names initials="N">Nivethika</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2176346"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kakkanat</surname><given-names initials="A">Anjali</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sam</surname><given-names initials="G">Gayathri</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2176345"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kabir</surname><given-names initials="MT">Md. Tanvir</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Rehm</surname><given-names initials="BHA">Bernd H. A.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/32140"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Centre for Cell Factories and Biopolymers (CCFB), Griffith Institute for Drug Discovery, Griffith University</institution>, <addr-line>Nathan, QLD</addr-line>, <country>Australia</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Menzies Health Institute Queensland (MHIQ), Griffith University</institution>, <addr-line>Gold Coast, QLD</addr-line>, <country>Australia</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Mahbuba Rahman, McMaster University, Canada</p></fn><fn fn-type="edited-by"><p>Reviewed by: Moza Alkowari, Hamad Medical Corporation, Qatar; Seetharama Konduru, Sidra Medicine, Qatar; Santosh Kumar Yadav, Johns Hopkins Medicine, United States</p></fn><corresp id="fn001">*Correspondence: Bernd H. A. Rehm, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:b.rehm@griffith.edu.au">b.rehm@griffith.edu.au</email>; Shuxiong Chen, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Shuxiong.chen@griffith.edu.au">Shuxiong.chen@griffith.edu.au</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>03</day><month>2</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">427662</issue-id><elocation-id>1131057</elocation-id><history><date date-type="received"><day>24</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>18</day><month>02</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-02-23 16:10:12.780"><day>23</day><month>02</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Chen, Pounraj, Sivakumaran, Kakkanat, Sam, Kabir and Rehm</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Chen, Pounraj, Sivakumaran, Kakkanat, Sam, Kabir and Rehm</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-14-1131057.pdf"/><abstract><p>Vaccines remain the best approach for the prevention of infectious diseases. Protein subunit vaccines are safe compared to live-attenuated whole cell vaccines but often show reduced immunogenicity. Subunit vaccines in particulate format show improved vaccine efficacy by inducing strong immune responses leading to protective immunity against the respective pathogens. Antigens with proper conformation and function are often required to induce functional immune responses. Production of such antigens requiring post-translational modifications and/or composed of multiple complex domains in bacterial hosts remains challenging. Here, we discuss strategies to overcome these limitations toward the development of particulate vaccines eliciting desired humoral and cellular immune responses. We also describe innovative concepts of assembling particulate vaccine candidates with complex antigens bearing multiple post-translational modifications. The approaches include non-covalent attachments (e.g. biotin-avidin affinity) and covalent attachments (e.g. SpyCatcher-SpyTag) to attach post-translationally modified antigens to particles.</p></abstract><kwd-group><kwd>particulate vaccine</kwd><kwd>cross-presentation</kwd><kwd>post-translational modification</kwd><kwd>dendritic cells</kwd><kwd>protective immunity</kwd><kwd>infectious diseases</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Australian Research Council
</institution><institution-id institution-id-type="doi">10.13039/501100000923</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn001">DP200100874</award-id></award-group><award-group><funding-source id="cn002"><institution-wrap><institution>Griffith University
</institution><institution-id institution-id-type="doi">10.13039/501100001791</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="2"/><equation-count count="0"/><ref-count count="113"/><page-count count="8"/><word-count count="4151"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Immunologic properties of soluble and particulate vaccines</title><p>Subunit vaccines contain selected immunogenic components of the pathogen to elicit an immune response (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Particulate vaccines involve the attachment of the antigens to microcarriers through chemical adsorption, encapsulation, conjugation, or biological self-assembly for enhanced delivery and induction of an efficient immune response (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Soluble vaccines are weakly immunogenic when compared to their insoluble counterparts such as when displayed on particulate carrier (<xref rid="B5" ref-type="bibr">5</xref>). Due to low immunogenicity, soluble vaccines often require the administration of multiple boosts (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). The use of immunostimulatory adjuvants along with soluble vaccines would improve the immune responses but potentially increases the overall vaccine production cost (<xref rid="B8" ref-type="bibr">8</xref>). However, antigens immobilized on particulate carrier exhibit enhanced immunogenicity (<xref rid="B9" ref-type="bibr">9</xref>&#8211;<xref rid="B11" ref-type="bibr">11</xref>). Some particulate carriers themselves act as adjuvants resulting in enhanced and targeted immune responses. Particulate carrier also allow the codelivery of adjuvants and multiple antigens to the same antigen presenting cells (APCs) (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Therefore, particulate vaccines are promising and potent antigen delivery systems to overcome the low immunogenicity of soluble subunit vaccine formulations.</p><p>The proposed mechanism of antigen processing elicited by soluble and particulate vaccine formulations is illustrated in <xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>. Soluble antigens can be internalized <italic toggle="yes">via</italic> endocytosis (<xref rid="B14" ref-type="bibr">14</xref>) and exclusively presented by major histocompatibility complex (MHC) II machinery in the endosomes, whereas particulate antigens above 500 nm can be phagocytosed by APCs into the phagosomes and presented by both MHC class I and II machineries in the cytosol (<xref rid="B7" ref-type="bibr">7</xref>). The maturation of the phagosome occurs after the formation of nascent phagosomes (pH 7.4) containing the engulfed particulate antigens which are then sequentially trafficked into progressive acidified compartments called early phagosome (pH 6), late phagosome (pH 5.5), and phagolysosomes (pH 5) (<xref rid="B15" ref-type="bibr">15</xref>). The efficient degradation of antigens into smaller peptides occurs in the phagolysosomes which contain a variety of digestive enzymes such as proteases, lipases, and glycosidases without degrading the epitopes (<xref rid="B16" ref-type="bibr">16</xref>). Further degradation of antigens into smaller polypeptides occurs in the cytosol by a protein complex called proteosomes (<xref rid="B17" ref-type="bibr">17</xref>). The degraded protein fragments will be transported into the endoplasmic reticulum, where the folding and assembly of the heavy and light chain of MHC molecules occurs and facilitates the MHC and peptide binding (<xref rid="B18" ref-type="bibr">18</xref>). Finally, the peptide-loaded MHC complex gets transported to the cell surface through the Golgi apparatus and attracts both CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells with specific receptors to mount a cell-mediated immune response eliminating the damaged/infected cells displaying corresponding peptide fragments (<xref rid="B19" ref-type="bibr">19</xref>). MHC class I and II pathways are usually involved presenting peptides from intracellular or extracellular pathogens, respectively. However, dendritic cells (DCs) possess the ability to divert peptides derived from extracellular pathogens to cytotoxic CD8<sup>+</sup> T cells <italic toggle="yes">via</italic> the MHC class I presentation pathway (<xref rid="B20" ref-type="bibr">20</xref>). A phagosome is a key organelle in antigen cross-presentation which primarily induces cytotoxic CD8<sup>+</sup> T cell responses. However, such responses mediated by the phagosome route are not achievable by endocytosed soluble antigens (<xref rid="B21" ref-type="bibr">21</xref>). In addition, B cell receptors (BCRs) are uniformly distributed on B cell surface in the absence of pathogen invasion. However, BCRs are brought together to bind multiple copies of antigens on the invading pathogen&#8217;s surface. This process is also called BCR cross-linking, required for B cell activation. Repetitive display of antigens on particles facilitates efficient recognition and BCR cross-linking, which allow strong B cell activation and antigen uptake for presentation to CD4<sup>+</sup> T cells. It results in inducing higher levels of neutralizing antibodies and functional cellular immune responses than achieved by soluble antigens present in most subunit vaccines (<xref rid="B22" ref-type="bibr">22</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Comparison of antigen processing pathways elicited by soluble and particulate antigen formulations.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-14-1131057-g001.jpg"/></fig><p>Soluble antigens are engulfed by APCs through endocytosis and get presented to endosomes. Consequently, endosomes fuse with lysosomes and degrade the antigens into peptide fragments restricted to both MHC class I and II. MHC class II specific peptides bind to MHC class II molecules by replacing the class II-associated invariant chain peptide (<xref rid="B23" ref-type="bibr">23</xref>). This peptide-MHC class II complex will get presented to the cell surface and activates na&#239;ve CD4<sup>+</sup> T cells. However, if the peptides are MHC class I specific, they will get cross-presented to proteosomes and follows MHC class-I pathway to expand cytotoxic CD8<sup>+</sup> T cells (<xref rid="B14" ref-type="bibr">14</xref>). Even though the cross-presentation of soluble antigen was detected <italic toggle="yes">in vivo</italic>, it is not very efficient in generating strong immune responses (<xref rid="B24" ref-type="bibr">24</xref>). However, unlike soluble antigens, particulate antigens are sustainably presented by APCs in large quantities for a prolonged time resulting in enhanced immunogenicity (<xref rid="B25" ref-type="bibr">25</xref>).</p></sec><sec id="s2"><title>Antigen delivery platforms and their immunological properties</title><sec id="s2_1"><title>Virus-like particles (VLPs)</title><p>Virus-like particles (VLPs) are nanostructures made up of self-assembled virus proteins. VLPs do not contain viral genomes and thus they do not have the capacity of infecting the host cell (<xref rid="B26" ref-type="bibr">26</xref>). VLPs can be generated by using bacterial, yeast, insect, plant, and mammalian cells (<xref rid="B27" ref-type="bibr">27</xref>). It has been reported that VLPs can serve as carriers for the delivery of various biomaterials and nanomaterials including vaccines (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>) (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). Currently, VLP-based vaccines against human papillomavirus, hepatitis B virus and malaria are commercially available (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>) (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B30" ref-type="bibr">30</xref>).</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Flow diagram of precision-engineering of subunit vaccine particles.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-14-1131057-g002.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Antigen delivery platforms and their immunological properties.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Virus-like particles</th><th valign="top" align="center" rowspan="1" colspan="1">Viral vector vaccines</th><th valign="top" align="center" rowspan="1" colspan="1">Messenger RNA (mRNA) vaccines</th><th valign="top" align="center" rowspan="1" colspan="1">Polymeric vaccines</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Components</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Nanostructures made up of self-assembled virus proteins but do not contain viral genomes</td><td valign="top" align="left" rowspan="1" colspan="1">Comprise a harmless, modified, and unrelated virus that delivers foreign genetic material (DNA)</td><td valign="top" align="left" rowspan="1" colspan="1">Deliver a transcript of interest that encodes a target antigen</td><td valign="top" align="left" rowspan="1" colspan="1">Natural and synthetic polymers are used to encapsulate a range of vaccine components</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Advantages</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Safe, presentation of multiple epitopes, highly immunogenic, induce both cellular and humoral immune responses</td><td valign="top" align="left" rowspan="1" colspan="1">Sustained immune responses, enhanced immunogenicity without the need for adjuvant co-administration, powerful cellular and antibody responses</td><td valign="top" align="left" rowspan="1" colspan="1">Rapid development, and a cell-free manufacturing process, safer and more effective than DNA-based vaccines, do not require nuclear entry, do not pose a risk of integration into the host genome, intrinsic self-adjuvant properties, exert potent cellular and humoral immune responses</td><td valign="top" align="left" rowspan="1" colspan="1">Induction of enhanced levels of antigen-specific antibodies, extended antigen circulation, co-loading of antigens, elevated level of cytokine release, strong cellular and humoral immune responses owing to their unique properties including their pathogen mimicking size, controllable lipophilicity/hydrophobicity, modifiable surfaces, and high surface-to-volume ratios, capable of delivering a wide range of antigenic molecules</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Disadvantages</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Instability, high manufacturing cost</td><td valign="top" align="left" rowspan="1" colspan="1">Expensive, highly complex,<break/>pose a risk for the environment and human health</td><td valign="top" align="left" rowspan="1" colspan="1">Limited transfection efficiency, degradation of free mRNA <italic toggle="yes">via</italic> nucleases, degradation of exogenous naked mRNA in the endolysosomal compartments</td><td valign="top" align="left" rowspan="1" colspan="1">Some chemically synthesized polymer materials (such as polyurethane) can&#8217;t be naturally degraded and may also cause environmental pollution, some inorganic material carriers show low immunogenicity and poor biodegradability</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Examples of licensed vaccines</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Human papillomavirus, hepatitis B virus, and malaria vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">Johnson &amp; Johnson&#8217;s Janssen (J&amp;J/Janssen) COVID-19 vaccine, Ebola virus vaccine (Ervebo)</td><td valign="top" align="left" rowspan="1" colspan="1">Moderna (mRNA-1273) and Pfizer-BioNTech (BNT162b2) COVID-19 vaccines</td><td valign="top" align="left" rowspan="1" colspan="1">Further clinical studies are needed for regulatory approval</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>References</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B30" ref-type="bibr">30</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B33" ref-type="bibr">33</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B36" ref-type="bibr">36</xref>&#8211;<xref rid="B46" ref-type="bibr">46</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B47" ref-type="bibr">47</xref>&#8211;<xref rid="B51" ref-type="bibr">51</xref>)</td></tr></tbody></table></table-wrap><p>VLP-based vaccines are highly immunogenic and can induce both cellular and humoral immune responses and the use of adjuvants enhances their immunogenicity (<xref rid="B32" ref-type="bibr">32</xref>). VLPs were found to strongly activate DCs (<xref rid="B32" ref-type="bibr">32</xref>). DCs are well-known as the most effective APCs and have the ability to activate both na&#970;ve and memory immune responses (<xref rid="B52" ref-type="bibr">52</xref>). Activation of DCs takes place owing to the binding of VLPs with the receptors that are present on the surface of DCs known as pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B53" ref-type="bibr">53</xref>). VLP-based vaccines are then recognized and internalized by DCs and get presented to CD4<sup>+</sup> helper T cells and cytotoxic CD8<sup>+</sup> T cells <italic toggle="yes">via</italic> MHC class II and MHC class I molecules, respectively (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B54" ref-type="bibr">54</xref>). VLPs allow presentation of multiple copies of epitopes on their surface, which mediate cross-linking of B cell receptors and subsequent priming B cells toward generation of antibodies even without the help of CD4<sup>+</sup> T helper cells (<xref rid="B32" ref-type="bibr">32</xref>). VLP-based vaccines are regarded safer as compared to attenuated or inactivated viruses. Nonetheless, instability of VLPs can compromise their immunogenicity and the production cost of some VLP-based vaccines can be high because of their low yields (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B31" ref-type="bibr">31</xref>).</p></sec><sec id="s2_2"><title>Viral vector vaccines (VVVs)</title><p>Viral vectors are considered as an advanced approach for the development of vaccines. Viral vectors have been used to produce vaccines against multiple infectious diseases including SARS-CoV-2, Ebola, Malaria, and HIV (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B55" ref-type="bibr">55</xref>). Viral vector vaccines (VVVs) comprise a harmless, modified, and unrelated virus that delivers foreign genetic material (DNA) to human cells, which then produce the pathogen-specific antigens encoded by the DNA (<xref rid="B33" ref-type="bibr">33</xref>). Moreover, VVVs offer multiple advantages as compared to other vaccine platforms including long-lasting immune responses, high immunogenicity without the need for adjuvant co-administration, and strong cellular and antibody responses (<xref rid="B34" ref-type="bibr">34</xref>).</p><p>Viral vectors such as based on adenovirus, poxvirus, influenza viruses, and measles virus are currently widely considered for the development of VVVs (<xref rid="B56" ref-type="bibr">56</xref>). Among them, the adenoviral vector has been used extensively to develop COVID-19 vaccines (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>). VVVs can induce long-lasting and strong cellular responses to eliminate virus-infected cells. Cytotoxic CD8<sup>+</sup> T cells rapidly proliferate and differentiate in response to antigens, while cell-mediated immunity induces natural killer cells and macrophages to eliminate intracellular pathogens (<xref rid="B58" ref-type="bibr">58</xref>). On the other hand, most of the VVVs can induce powerful humoral immunity, however it has been observed that immunogen design can affect VVV-mediated humoral immunogenicity (<xref rid="B58" ref-type="bibr">58</xref>). For example, Huang et&#160;al. (<xref rid="B59" ref-type="bibr">59</xref>) revealed that immunizing mice or hamsters with SARS-CoV-2 spike proteins lacking glycan shields induced potent and broadly reactive immune responses. Despite many advantages, the production process of VVVs is comparatively expensive and highly complex. Moreover, VVVs could pose a risk for the environment and human health (<xref rid="B35" ref-type="bibr">35</xref>).</p></sec><sec id="s2_3"><title>Messenger RNA (mRNA) vaccines</title><p>Messenger RNA (mRNA) vaccines have already been found highly effective against various infectious diseases (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B60" ref-type="bibr">60</xref>). There are several advantages offered by mRNA vaccines including rapid development, and a cell-free manufacturing process (<xref rid="B36" ref-type="bibr">36</xref>). mRNA vaccine technology involves delivering a transcript of interest that encodes a target antigen (<xref rid="B37" ref-type="bibr">37</xref>). There are two categories of mRNA vaccines including self-amplifying and non-replicating mRNA vaccines (<xref rid="B61" ref-type="bibr">61</xref>). mRNA vaccines precisely encode the specific antigen of interest, and then cells that take up the mRNA can translate it into proteins (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Subsequently, the immune system mounts robust adaptive immune responses against the target proteins (<xref rid="B63" ref-type="bibr">63</xref>). mRNA vaccines are safer and more effective than DNA-based vaccines, since mRNA vaccines do not require nuclear entry and they do not pose a risk of integration into the host genome (<xref rid="B38" ref-type="bibr">38</xref>&#8211;<xref rid="B40" ref-type="bibr">40</xref>). In addition, since the outbreak of the COVID-19 pandemic, there is a growing research interest in mRNA vaccines because of their capacity to trigger strong immune responses, rapid development, and simple manufacturing process (<xref rid="B64" ref-type="bibr">64</xref>). Currently approved mRNA COVID-19 vaccines include Moderna (mRNA-1273) and Pfizer-BioNTech (BNT162b2) (<xref rid="B41" ref-type="bibr">41</xref>&#8211;<xref rid="B43" ref-type="bibr">43</xref>).</p><p>mRNA vaccines contain intrinsic self-adjuvant properties and exert potent cellular and humoral immune responses (<xref rid="B65" ref-type="bibr">65</xref>). Hence mRNA vaccines have the potential to induce both innate and adaptive immune responses. mRNA vaccines also generated strong immune responses in experimental animal models of various infectious diseases including rabies, Zika virus disease, and influenza (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>). Following the delivery of mRNA vaccines in the body, they are taken up by APCs such as DCs or macrophages. Subsequently, they escape the endosome and enter into the cytosol, where mRNA is translated into protein by the ribosome (<xref rid="B68" ref-type="bibr">68</xref>). In the lymph node, antigen derived peptides are presented <italic toggle="yes">via</italic> MHC class I or II to cytotoxic CD8<sup>+</sup> T cells or CD4<sup>+</sup> T cells, which ultimately results in the activation of cell-mediated and humoral immune responses (<xref rid="B69" ref-type="bibr">69</xref>). However, there are some drawbacks of mRNA vaccines that need to be addressed to develop more effective, stable, and safe mRNA vaccines. These drawbacks include limited transfection efficiency, degradation of free mRNA <italic toggle="yes">via</italic> nucleases, and degradation of exogenous naked mRNA in the endolysosomal compartments (<xref rid="B44" ref-type="bibr">44</xref>&#8211;<xref rid="B46" ref-type="bibr">46</xref>). In addition, rare evidence was found that severe anaphylaxis and myocarditis occurred after immunization with mRNA-containing lipid nanoparticles (mRNA-LNP). It is believed that the lipid component, polyethylene glycol (PEG) 2000, in the vaccine formulation causes anaphylactic shock, especially in those who already have pre-existing anti-PEG antibodies (<xref rid="B70" ref-type="bibr">70</xref>).</p></sec><sec id="s2_4"><title>Polymeric vaccines</title><p>There is a growing interest in polymer-based vaccines because of their several beneficial properties including induction of enhanced levels of antigen-specific antibodies, extended antigen circulation, co-loading of antigens, elevated level of cytokine release, and potent cellular immune responses (<xref rid="B47" ref-type="bibr">47</xref>). Polymer-based particles can be used as vaccine platforms to deliver numerous antigenic molecules including nucleic acids, carbohydrates, cell lysates, lipopeptides, peptides, and proteins (<xref rid="B71" ref-type="bibr">71</xref>). Polymer-based particles have great potential in the prevention and treatment of infectious diseases (<xref rid="B51" ref-type="bibr">51</xref>). Lipid- and polymer-based NPs have already been extensively studied in vaccine development. NPs have the capacity to induce strong cellular and humoral immune responses owing to their unique properties including their pathogen mimicking size, controllable lipophilicity/hydrophobicity, modifiable surfaces, and high surface-to-volume ratios (<xref rid="B48" ref-type="bibr">48</xref>).</p><p>There are two major groups of biodegradable polymers such as natural and synthetic polymers. A range of both synthetic and natural biodegradable polymers have already been studied for the development of vaccines. Naturally occurring biomaterials including various proteins including silk, fibrin, and collagen, and several polysaccharides including hyaluronic acid derivatives, chitosan, alginate, and starch have widely been studied to prepare particulate vaccine formulations (<xref rid="B72" ref-type="bibr">72</xref>). On the other hand, many synthetic biodegradable polymers including polyanhydrides, polyphosphazene, and various polyesters including poly(lactic-co-glycolic acid), polyglycolide, polycaprolactone, and polylactides have been studied as potential vaccine delivery systems (<xref rid="B73" ref-type="bibr">73</xref>).</p><p>Polyhydroxyalkanoates (PHAs) have been identified as biocompatible and biodegradable biopolymers and that are produced by a range of bacteria serving as energy and carbon storage materials (<xref rid="B74" ref-type="bibr">74</xref>). PHAs have drawn a lot of attention because of their potential as particulate vaccines in delivering various antigens from diverse pathogens (<xref rid="B75" ref-type="bibr">75</xref>). Furthermore, PHA particles displaying one or more antigens already exhibited improved cell-mediated and humoral immune responses when compared to the corresponding soluble subunit vaccines (<xref rid="B49" ref-type="bibr">49</xref>). Extensive animal trials have already confirmed that PHA particle vaccine candidates are safe and have the potential to induce robust and protective immune responses against bacterial and viral pathogens (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>) (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B85" ref-type="bibr">85</xref>). Despite the great potential of polymeric nanostructured vaccines, further clinical studies are needed towards regulatory approval (<xref rid="B51" ref-type="bibr">51</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>PHA particle vaccines with protective immunity against various infectious pathogens.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Pathogen</th><th valign="top" align="center" rowspan="1" colspan="1">Selected antigen/epitopes</th><th valign="top" align="center" rowspan="1" colspan="1">Animal model</th><th valign="top" align="center" rowspan="1" colspan="1">Humoral responses</th><th valign="top" align="center" rowspan="1" colspan="1">T cell responses</th><th valign="top" align="center" rowspan="1" colspan="1">Protective Immunity</th><th valign="top" align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus suis</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">SSU1915, SSU1355, SSU0185, SSU1215, SSU1773</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse</td><td valign="top" align="left" rowspan="1" colspan="1">IgG, IgM</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B76" ref-type="bibr">76</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Mycobacterium tuberculosis</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">H4, H28</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse</td><td valign="top" align="left" rowspan="1" colspan="1">IgG, IgG1, IgG2c</td><td valign="top" align="left" rowspan="1" colspan="1">Th1, Th2, Th17</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B11" ref-type="bibr">11</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Plasmodium falciparum</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">B/T cell epitopes of CSP</td><td valign="top" align="left" rowspan="1" colspan="1">Sheep</td><td valign="top" align="left" rowspan="1" colspan="1">IgG</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B77" ref-type="bibr">77</xref>)</td></tr><tr><td valign="top" rowspan="2" align="left" colspan="1">
<italic toggle="yes">SARS-CoV-2</italic>
</td><td valign="top" rowspan="2" align="left" colspan="1">S1, N, SM epitopes</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse</td><td valign="top" align="left" rowspan="1" colspan="1">IgG, IgG1, IgG2c</td><td valign="top" align="left" rowspan="1" colspan="1">Th1, Th2</td><td valign="top" rowspan="2" align="left" colspan="1">Yes</td><td valign="top" rowspan="2" align="left" colspan="1">(<xref rid="B78" ref-type="bibr">78</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hamster</td><td valign="top" align="left" rowspan="1" colspan="1">IgG neutralizing ab</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Pseudomonas aeruginosa</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Oprl, OprF, AlgE,<break/>OprL, PopB, PilA, PilO, FliC, Hcp1, CdrA</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse</td><td valign="top" align="left" rowspan="1" colspan="1">IgG, IgG1, IgG2a, IgG2c<break/>Opsonophagocytic antibodies</td><td valign="top" align="left" rowspan="1" colspan="1">Th1, Th2</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Hepatitis C virus</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">HCc</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1, IgG2c</td><td valign="top" align="left" rowspan="1" colspan="1">Th1, Th2, Th17</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B81" ref-type="bibr">81</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Mycobacterium tuberculosis</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Ag85A and ESAT-6</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Th1, Th2, Th17</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B82" ref-type="bibr">82</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus pneumoniae</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">PsaA, Ply, Serotype 19F CPS</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1, IgG2c<break/>Opsonophagocytic antibodies</td><td valign="top" align="left" rowspan="1" colspan="1">Th1, Th2</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B83" ref-type="bibr">83</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Neisseria meningitidis</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Serogroup C CPS, NadA, fHbp</td><td valign="top" align="left" rowspan="1" colspan="1">Mouse</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1, IgG2a, IgG2b, IgG3</td><td valign="top" align="left" rowspan="1" colspan="1">Th1, Th2, Th17</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B84" ref-type="bibr">84</xref>)</td></tr></tbody></table></table-wrap><p>In a recent study, the immunogenic carrier protein, CRM197 (non-toxic variant diphtheria toxin) was engineered for the assembly of antigen-containing submicron-sized particles (<xref rid="B86" ref-type="bibr">86</xref>). Chen et&#160;al. (2022) developed a bioprocess for high-yield production <italic toggle="yes">via</italic> efficient assembly inside engineered endotoxin-free <italic toggle="yes">Escherichia coli.</italic> These particles were ambient-temperature stable and were precision engineered to serve as vaccine candidates that induce protective immunity against SARS-CoV-2, <italic toggle="yes">Mycobacterium tuberculosis</italic> and group A Streptococcus, respectively. The study demonstrated the utility and versatility of engineering immunogenic carrier proteins, that have been approved in vaccine formulation, into a synthetic particulate vaccine for induction of functional humoral and T cell-mediated immune responses (<xref rid="B86" ref-type="bibr">86</xref>).</p></sec></sec><sec id="s3"><title>Strategies to enhance immunogenicity of particulate vaccines</title><p>The ultimate aim of vaccination is to induce protective immunity against pathogens (<xref rid="B10" ref-type="bibr">10</xref>). The addition of adjuvants can further enhance and/or modulate the immunogenicity of particulate vaccines resulting in enhanced vaccine performance (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B84" ref-type="bibr">84</xref>). Induction of protective immunity requires effective priming of T and B cells (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B87" ref-type="bibr">87</xref>). The activation and effector phases of T cell-mediated responses require two signals, &#8220;signal one&#8221; through T cell receptor recognition of peptide-MHC complexes and &#8220;signal two&#8221; <italic toggle="yes">via</italic> costimulatory receptors on T cells. Both signals are provided by APCs that encounter pathogens (<xref rid="B1" ref-type="bibr">1</xref>). Adjuvants can stimulate the activation and maturation of APCs, such as DCs, and thus enhance the expression of MHC and co-stimulatory molecules, which are essential for the induction of adaptive immunity (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Adjuvants are usually categorized as the delivery system (such as lipid vesicles) or immunostimulatory molecules (such as PRR ligands) based on their proposed mechanism. Most adjuvants possess both properties (<xref rid="B88" ref-type="bibr">88</xref>). For example, alum salts promote Th2-type immunity and B cell differentiation, leading to tremendous antibody production (<xref rid="B78" ref-type="bibr">78</xref>). Adjuvant System 04 (AS04) is a combination adjuvant, consisting of alum salts and TLR4 ligand monophosphoryl lipid A, which respectively upregulate potent humoral (Th2) and cellular (Th1) immune responses (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>) (<xref rid="B88" ref-type="bibr">88</xref>).</p><p>As PRR ligands enable innate recognition by PRR, such as TLRs, present on DCs, the fabrication of particulate vaccines with PRR ligands can lead to targeted delivery to DCs and enhance the effectiveness of particulate vaccines (<xref rid="B89" ref-type="bibr">89</xref>). This enhancement is achieved by inducing &#8220;signal two&#8221; through the expression of co-stimulatory molecules on DCs, which augments T-cell responses (<xref rid="B89" ref-type="bibr">89</xref>). Thus coupling PRR ligands with antigens confer innate activation and antigenic stimulation to the same DC that uptakes the particulate vaccine. This lead to the generation of both signals, MHC-peptide complex and co-stimulatory signal, required for T-cell activation (<xref rid="B1" ref-type="bibr">1</xref>). In addition, targeted delivery to DCs can alternatively be achieved through the co-delivery of the CD40 ligand with antigen. The ligation of the CD40 ligand with the CD40 receptor on DCs serves as a key co-stimulator for DCs maturation and induction of CD4<sup>+</sup> T cell responses (<xref rid="B90" ref-type="bibr">90</xref>).</p><p>The ability of DCs to present extracellular antigens in the context of MHC class I, a phenomenon called cross-presentation, can be an ideal target for the targeted delivery of vaccine antigens (<xref rid="B20" ref-type="bibr">20</xref>). Adjuvants such as MF59 and QS-21 in combination with TLR ligands can facilitate cytosolic or vacuole pathways of cross-presentation (<xref rid="B91" ref-type="bibr">91</xref>). In addition, cell-penetrating peptides (CPPs) also known as protein translocation domains or membrane translocating sequences, are small peptides with strong membrane permeability. CPPs are comprised of 6 to 30 amino acid residues and majority of them are basic amino acid residues, leading to an overall positive net charge (<xref rid="B92" ref-type="bibr">92</xref>&#8211;<xref rid="B94" ref-type="bibr">94</xref>). Recently the use of arginine- and lysine-rich CPPs in conjunction with particulate vaccines promotes the MHC class I pathway cross-presentation effectively against viral and tumor antigens (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B93" ref-type="bibr">93</xref>). Moreover, DC targeting peptides (DCpep) are strongly targeted to DCs. They can improve vaccine capture efficiency, and promote DCs maturation, cytokine secretion, and T cell proliferation. Vaccines with DCpep can significantly induce stronger immune responses than the vaccines without DCpep (<xref rid="B95" ref-type="bibr">95</xref>). For example, Clec9A is produced on various DC subsets, such as mouse CD8a<sup>+</sup> DCs and CD103<sup>+</sup> DCs, and responsible for antigen cross-presentation. CBP-12 has high affinity with Clec9A on DCs. Vaccines with CBP-12 has been shown to elicit both strong cytotoxic CD8<sup>+</sup> T cell and antibody responses (<xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B97" ref-type="bibr">97</xref>).</p></sec><sec id="s4"><title>Particulate vaccine fabrication strategies</title><p>Post-translational modifications (PTMs) regulate function of proteins including antigens and contribute to their immunological properties and stability (<xref rid="B98" ref-type="bibr">98</xref>). A study showed that PTMs are often required for antigens to induce functional immune responses (<xref rid="B98" ref-type="bibr">98</xref>). Over the last decade, an increasing number of PTMs have been detected and characterized in <italic toggle="yes">E. coli</italic>, and most PTMs are rarely found in bacterial antigens with the majority of modified antigens having a low sub-stoichiometric degree of modification (<xref rid="B99" ref-type="bibr">99</xref>). As a result, retaining the conformation and function of eukaryotic multi-domain antigens produced in <italic toggle="yes">E. coli</italic> is more challenging (<xref rid="B100" ref-type="bibr">100</xref>).</p><p>Although the <italic toggle="yes">E. coli</italic> expression system is commonly used to produce recombinant protein vaccines, mammalian or insect cells should be considered for antigens that require high levels of PTMs that are required for vaccine purposes (<xref rid="B98" ref-type="bibr">98</xref>, <xref rid="B101" ref-type="bibr">101</xref>). These post-translationally modified complex antigens can then be incorporated into particulate platforms using a variety of methods (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>). Non-covalent methods include the use of peptide tags like polyhistidine, protein tags such as maltose-binding protein and glutathione- <italic toggle="yes">S</italic>-transferase, DNA-directed immobilization, and the biotin&#8211;streptavidin pair (<xref rid="B102" ref-type="bibr">102</xref>). One of the most powerful non-covalent biological interactions known is the binding of biotin to avidin (<xref rid="B103" ref-type="bibr">103</xref>). Purified post-translationally modified complex antigens that have been biotin labelled are therefore highly effective for protein capture on particulate platforms for vaccine delivery, and the biotinylated antigens are subsequently recognized by avidin/streptavidin. Although chemical biotinylation frequently results in heterogeneous products with impaired function (<xref rid="B104" ref-type="bibr">104</xref>), enzymatic biotinylation with <italic toggle="yes">E. coli</italic> biotin ligase (BirA) attaches biotin to the 15 amino acid avidin tag (AviTag) peptide yielding a homogeneous product with a high yield (<xref rid="B105" ref-type="bibr">105</xref>). Streptavidin is used as a potent immunostimulant in less immunogenic antigen-based vaccines, most notably cancer vaccines, in addition to binding to the biotinylated antigen (<xref rid="B106" ref-type="bibr">106</xref>).</p><p>Although the interaction between streptavidin and biotin is strong, the binding can be destroyed by molecular motors (such as FtsK) in seconds (<xref rid="B107" ref-type="bibr">107</xref>) or shear forces in milliseconds (<xref rid="B108" ref-type="bibr">108</xref>), making it challenging to implement barriers or locks in cellular systems. Vaccine stability is required not just during storage but also following injection, where the lower concentration and other circumstances, such as endosomal pH and shear stress in the circulation, may mediate the dissociation of non-covalently attached antigens from particles (<xref rid="B109" ref-type="bibr">109</xref>). Therefore, covalent interaction between the target antigen and carriers is considered as a distinct, more robust, and long-lasting method of attaching antigens to the surface of an antigen carrier. Covalent linkage to peptide tags can be accomplished using SortaseA, SNAP-tag, split inteins, HaloTag, click reactions and Electrostatic Interaction Locks; however, SpyCatcher/SpyTag technology is most commonly used in vaccine delivery because SpyCatcher forms intermolecular isopeptide bonds selectively and spontaneously with SpyTag without the need for additional enzymes or chemical catalysis (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B105" ref-type="bibr">105</xref>). Furthermore, in comparison, SpyCatcher/SpyTag chemistry is reactive at the terminal and internal sites of a protein and can improve protein stability without changing its function (<xref rid="B110" ref-type="bibr">110</xref>). Thus, the bacterial production host can be bioengineered to produce vaccine particles displaying SpyCatcher to enable specific immobilization of SpyTag-fused target antigens with proper PTMs produced by such as mammalian or insect cell cultures (<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B112" ref-type="bibr">112</xref>). However, several limitations typically may restrict the use of SpyCatcher/SpyTag in vaccine delivery. The final construct contains around 17 kDa molecular scar left by SpyCatcher/SpyTag coupling unlike the sortaseA with a smaller scar or split intein with no scar. Moreover, SpyCatcher/SpyTag is derived from <italic toggle="yes">Streptococcus pyogenes</italic>. The potential immunogenicity problem related to its bacterial origin may be an issue for vaccine design (<xref rid="B113" ref-type="bibr">113</xref>).</p></sec><sec id="s5"><title>Conclusion and future perspectives</title><p>Antigens delivered in particulate form show superior immunological properties when compared to corresponding antigens in soluble forms. APCs, such as DCs, can cross-present antigens taken up in particulate form to potently activate both cytotoxic CD8<sup>+</sup> and CD4<sup>+</sup> T cells. Particulate vaccines are versatile as they can be formulated with adjuvants and/or bioengineered for the co-delivery of antigens with PRR ligands, CPPs, and DCpep for induction of protective immunity. Immobilizing antigens to particulate carriers significantly enhances their stability such as enabling the generation of ambient-temperature stable vaccine formulations. Bacterial production hosts are unable to produce complex antigens with high levels of PTMs. This review highlighted the advances of using various technologies <italic toggle="yes">via</italic> covalent and non-covalent attachments to incorporate antigens with PTMs on particles. Although particle vaccines possess a great promise to combat infectious diseases, there are still a number of unknowns. These include a profound understanding of how particle size, charge, and structure influence the induction of immune responses. Safety concerns, such as severe anaphylaxis and myocarditis, have also been raised due to the extensive use of some new nanoparticle vaccines, such as mRNA-LNP. Understanding the underlying mechanisms of nanoparticle vaccine properties and potential toxicity could significantly advance the rational design of prophylactic and therapeutic nanoparticle vaccines.</p></sec><sec sec-type="author-contributions" id="s6"><title>Author contributions</title><p>All authors contributed to the manuscript. SC and BR conceived and revised the manuscript. All authors contributed to the article and approved the submitted version.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Katharina Gabriela Spaniol, at Griffith University, to provide Saranya Pounraj access to Biorender to draw a licensed figure. This work is supported by the Griffith Institute for Drug Discovery, Griffith University (Australia) and the Centre for Cell Factories and Biopolymers, Griffith University (Australia). BR acknowledges financial support from the award of the Australian Research Council (ARC) Discovery Project (DP200100874) and the ARC Linkage Infrastructure, Equipment and Facilities (LE200100140).</p></ack><sec sec-type="COI-statement" id="s7"><title>Conflict of interest</title><p>Author BHAR is an inventor of the biopolymer particle technology and co-founder/shareholder of Polybatics Ltd. BHAR and SC are inventors on a patent application describing the immunogenic carrier protein CRM197 vaccine platform and its uses.</p><p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s8"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Miro</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Gonzaga</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Evert</surname><given-names>B</given-names></name><name name-style="western"><surname>Wibowo</surname><given-names>D</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>BH</given-names></name></person-group>. <article-title>Polyester as antigen carrier toward particulate vaccines</article-title>. <source>Biomacromolecules</source> (<year>2019</year>) <volume>20</volume>(<issue>9</issue>):<page-range>3213&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.biomac.9b00509</pub-id><pub-id pub-id-type="pmid">31122016</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Mahalingam</surname><given-names>M</given-names></name><name name-style="western"><surname>Batra</surname><given-names>H</given-names></name><name name-style="western"><surname>Rao</surname><given-names>VB</given-names></name></person-group>. <article-title>Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases</article-title>. <source>Adv Drug Deliv Rev</source> (<year>2019</year>) <volume>145</volume>:<fpage>57</fpage>&#8211;<lpage>72</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.addr.2018.06.025</pub-id><pub-id pub-id-type="pmid">29981801</pub-id><pub-id pub-id-type="pmcid">PMC6759415</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seyfoori</surname><given-names>A</given-names></name><name name-style="western"><surname>Shokrollahi Barough</surname><given-names>M</given-names></name><name name-style="western"><surname>Mokarram</surname><given-names>P</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mehrbod</surname><given-names>P</given-names></name><name name-style="western"><surname>Sheidary</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Emerging advances of nanotechnology in drug and vaccine delivery against viral associated respiratory infectious diseases (Varid)</article-title>. <source>Int J Mol Sci</source> (<year>2021</year>) <volume>22</volume>(<issue>13</issue>):<elocation-id>6937</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms22136937</pub-id><pub-id pub-id-type="pmid">34203268</pub-id><pub-id pub-id-type="pmcid">PMC8269337</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pielenhofer</surname><given-names>J</given-names></name><name name-style="western"><surname>Sohl</surname><given-names>J</given-names></name><name name-style="western"><surname>Windbergs</surname><given-names>M</given-names></name><name name-style="western"><surname>Langguth</surname><given-names>P</given-names></name><name name-style="western"><surname>Radsak</surname><given-names>MP</given-names></name></person-group>. <article-title>Current progress in particle-based systems for transdermal vaccine delivery</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>266</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2020.00266</pub-id><pub-id pub-id-type="pmid">32174915</pub-id><pub-id pub-id-type="pmcid">PMC7055421</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snapper</surname><given-names>CM</given-names></name></person-group>. <article-title>Distinct immunologic properties of soluble versus particulate antigens</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>598</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.00598</pub-id><pub-id pub-id-type="pmid">29619034</pub-id><pub-id pub-id-type="pmcid">PMC5871672</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jhaveri</surname><given-names>J</given-names></name><name name-style="western"><surname>Raichura</surname><given-names>Z</given-names></name><name name-style="western"><surname>Khan</surname><given-names>T</given-names></name><name name-style="western"><surname>Momin</surname><given-names>M</given-names></name><name name-style="western"><surname>Omri</surname><given-names>A</given-names></name></person-group>. <article-title>Chitosan nanoparticles-insight into properties, functionalization and applications in drug delivery and theranostics</article-title>. <source>Molecules</source> (<year>2021</year>) <volume>26</volume>(<issue>2</issue>):<elocation-id>272</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/molecules26020272</pub-id><pub-id pub-id-type="pmid">33430478</pub-id><pub-id pub-id-type="pmcid">PMC7827344</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gala</surname><given-names>RP</given-names></name><name name-style="western"><surname>Bajaj</surname><given-names>L</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>A</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>KB</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>D</given-names></name><name name-style="western"><surname>Menon</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Oral vaccine delivery: The coming age of particulate vaccines to elicit mucosal immunity</article-title>. <source>Mucosal Deliv Drugs Biol Nanoparticles Springer</source> (<year>2020</year>) <volume>. p</volume>:<page-range>155&#8211;75</page-range>. doi: <pub-id pub-id-type="doi">10.1007/978-3-030-35910-2_7</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name><name name-style="western"><surname>Lodaya</surname><given-names>RN</given-names></name><name name-style="western"><surname>Lofano</surname><given-names>G</given-names></name></person-group>. <article-title>The continued advance of vaccine adjuvants&#8211;&#8217;We can work it out&#8217;</article-title>. In: <source>Seminars in immunology</source>. <publisher-name>Elsevier</publisher-name> (<year>2020</year>). doi: <pub-id pub-id-type="doi">10.1016/j.smim.2020.101426</pub-id><pub-id pub-id-type="pmid">33257234</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evert</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>McConville</surname><given-names>R</given-names></name><name name-style="western"><surname>Steel</surname><given-names>RW</given-names></name><name name-style="western"><surname>Healer</surname><given-names>J</given-names></name><name name-style="western"><surname>Boddey</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Epitope-coated polymer particles elicit neutralising antibodies against plasmodium falciparum sporozoites</article-title>. <source>NPJ Vaccines</source> (<year>2021</year>) <volume>6</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41541-021-00408-2</pub-id><pub-id pub-id-type="pmid">34845267</pub-id><pub-id pub-id-type="pmcid">PMC8630014</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wibowo</surname><given-names>D</given-names></name><name name-style="western"><surname>Jorritsma</surname><given-names>SH</given-names></name><name name-style="western"><surname>Gonzaga</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Evert</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>BH</given-names></name></person-group>. <article-title>Polymeric nanoparticle vaccines to combat emerging and pandemic threats</article-title>. <source>Biomaterials</source> (<year>2021</year>) <volume>268</volume>:<elocation-id>120597</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120597</pub-id><pub-id pub-id-type="pmid">33360074</pub-id><pub-id pub-id-type="pmcid">PMC7834201</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Quan</surname><given-names>DH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XT</given-names></name><name name-style="western"><surname>Sandford</surname><given-names>S</given-names></name><name name-style="western"><surname>Kirman</surname><given-names>JR</given-names></name><name name-style="western"><surname>Britton</surname><given-names>WJ</given-names></name><etal/></person-group>. <article-title>Particulate mycobacterial vaccines induce protective immunity against tuberculosis in mice</article-title>. <source>Nanomaterials</source> (<year>2021</year>) <volume>11</volume>(<issue>8</issue>):<elocation-id>2060</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/nano11082060</pub-id><pub-id pub-id-type="pmid">34443891</pub-id><pub-id pub-id-type="pmcid">PMC8402087</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Han</surname><given-names>T</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Versatile functionalization of ferritin nanoparticles by intein-mediated trans-splicing for antigen/adjuvant co-delivery</article-title>. <source>Nano Lett</source> (<year>2019</year>) <volume>19</volume>(<issue>8</issue>):<page-range>5469&#8211;75</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.nanolett.9b01974</pub-id><pub-id pub-id-type="pmid">31251065</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy</article-title>. <source>Acta Biomater</source> (<year>2019</year>) <volume>85</volume>:<fpage>1</fpage>&#8211;<lpage>26</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.actbio.2018.12.028</pub-id><pub-id pub-id-type="pmid">30579043</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgdorf</surname><given-names>S</given-names></name><name name-style="western"><surname>Kurts</surname><given-names>C</given-names></name></person-group>. <article-title>Endocytosis mechanisms and the cell biology of antigen presentation</article-title>. <source>Curr Opin Immunol</source> (<year>2008</year>) <volume>20</volume>(<issue>1</issue>):<fpage>89</fpage>&#8211;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.coi.2007.12.002</pub-id><pub-id pub-id-type="pmid">18249105</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blander</surname><given-names>JM</given-names></name></person-group>. <article-title>Regulation of the cell biology of antigen cross presentation</article-title>. <source>Annu Rev Immunol</source> (<year>2018</year>) <volume>36</volume>:<fpage>717</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1146/annurev-immunol-041015-055523</pub-id><pub-id pub-id-type="pmid">29490164</pub-id><pub-id pub-id-type="pmcid">PMC6430635</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taefehshokr</surname><given-names>N</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name><name name-style="western"><surname>Heit</surname><given-names>B</given-names></name></person-group>. <article-title>Rab gtpases in the differential processing of phagocytosed pathogens versus efferocytosed apoptotic cells</article-title>. <source>Histol Histopathol</source> (<year>2021</year>) <volume>36</volume>:<page-range>123&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.14670/HH-18-252</pub-id><pub-id pub-id-type="pmid">32990320</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desjardins</surname><given-names>M</given-names></name></person-group>. <article-title>Antigen cross-presentation: Proteasome location, location, location</article-title>. <source>EMBO J</source> (<year>2019</year>) <volume>38</volume>(<issue>16</issue>):<elocation-id>e102799</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.15252/embj.2019102799</pub-id><pub-id pub-id-type="pmid">31364184</pub-id><pub-id pub-id-type="pmcid">PMC6694217</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fountain</surname><given-names>A</given-names></name><name name-style="western"><surname>Inpanathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Alves</surname><given-names>P</given-names></name><name name-style="western"><surname>Verdawala</surname><given-names>MB</given-names></name><name name-style="western"><surname>Botelho</surname><given-names>RJ</given-names></name></person-group>. <article-title>Phagosome maturation in macrophages: Eat, digest, adapt, and repeat</article-title>. <source>Adv Biol Regul</source> (<year>2021</year>) <volume>82</volume>:<elocation-id>100832</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jbior.2021.100832</pub-id><pub-id pub-id-type="pmid">34717137</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>FM</given-names></name><name name-style="western"><surname>Colbert</surname><given-names>JD</given-names></name><name name-style="western"><surname>Rock</surname><given-names>KL</given-names></name></person-group>. <article-title>The gtp ase Rab39a promotes phagosome maturation into mhc-I antigen-presenting compartments</article-title>. <source>EMBO J</source> (<year>2020</year>) <volume>39</volume>(<issue>2</issue>):<elocation-id>e102020</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.15252/embj.2019102020</pub-id><pub-id pub-id-type="pmid">31821587</pub-id><pub-id pub-id-type="pmcid">PMC6960445</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wylie</surname><given-names>B</given-names></name><name name-style="western"><surname>Ong</surname><given-names>F</given-names></name><name name-style="western"><surname>Belhoul-Fakir</surname><given-names>H</given-names></name><name name-style="western"><surname>Priebatsch</surname><given-names>K</given-names></name><name name-style="western"><surname>Bogdawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Stirnweiss</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Targeting cross-presentation as a route to improve the efficiency of peptide-based cancer vaccines</article-title>. <source>Cancers (Basel)</source> (<year>2021</year>) <volume>13</volume>(<issue>24</issue>). doi:&#160;<pub-id pub-id-type="doi">10.3390/cancers13246189</pub-id><pub-id pub-id-type="pmcid">PMC8699136</pub-id><pub-id pub-id-type="pmid">34944809</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donahue</surname><given-names>ND</given-names></name><name name-style="western"><surname>Acar</surname><given-names>H</given-names></name><name name-style="western"><surname>Wilhelm</surname><given-names>S</given-names></name></person-group>. <article-title>Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine</article-title>. <source>Adv Drug Deliv Rev</source> (<year>2019</year>) <volume>143</volume>:<fpage>68</fpage>&#8211;<lpage>96</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.addr.2019.04.008</pub-id><pub-id pub-id-type="pmid">31022434</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z-H</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z-F</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W-H</given-names></name><name name-style="western"><surname>He</surname><given-names>F</given-names></name></person-group>. <article-title>A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles</article-title>. <source>J Nanobiotechnol</source> (<year>2022</year>) <volume>20</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>17</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12951-022-01710-4</pub-id><pub-id pub-id-type="pmcid">PMC9685936</pub-id><pub-id pub-id-type="pmid">36424615</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roche</surname><given-names>PA</given-names></name><name name-style="western"><surname>Furuta</surname><given-names>K</given-names></name></person-group>. <article-title>The ins and outs of mhc class ii-mediated antigen processing and presentation</article-title>. <source>Nat Rev Immunol</source> (<year>2015</year>) <volume>15</volume>(<issue>4</issue>):<page-range>203&#8211;16</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri3818</pub-id><pub-id pub-id-type="pmcid">PMC6314495</pub-id><pub-id pub-id-type="pmid">25720354</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>H</given-names></name><name name-style="western"><surname>Ackerman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Cody</surname><given-names>V</given-names></name><name name-style="western"><surname>Giodini</surname><given-names>A</given-names></name><name name-style="western"><surname>Hinson</surname><given-names>ER</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles</article-title>. <source>Immunology</source> (<year>2006</year>) <volume>117</volume>(<issue>1</issue>):<fpage>78</fpage>&#8211;<lpage>88</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1365-2567.2005.02268.x</pub-id><pub-id pub-id-type="pmid">16423043</pub-id><pub-id pub-id-type="pmcid">PMC1782199</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>B</given-names></name><name name-style="western"><surname>Maharjan</surname><given-names>S</given-names></name><name name-style="western"><surname>Cho</surname><given-names>K-H</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L</given-names></name><name name-style="western"><surname>Park</surname><given-names>I-K</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y-J</given-names></name><etal/></person-group>. <article-title>Chitosan-based particulate systems for the delivery of mucosal vaccines against infectious diseases</article-title>. <source>Int J Biol Macromol</source> (<year>2018</year>) <volume>110</volume>:<fpage>54</fpage>&#8211;<lpage>64</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ijbiomac.2017.10.101</pub-id><pub-id pub-id-type="pmid">29054527</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nooraei</surname><given-names>S</given-names></name><name name-style="western"><surname>Bahrulolum</surname><given-names>H</given-names></name><name name-style="western"><surname>Hoseini</surname><given-names>ZS</given-names></name><name name-style="western"><surname>Katalani</surname><given-names>C</given-names></name><name name-style="western"><surname>Hajizade</surname><given-names>A</given-names></name><name name-style="western"><surname>Easton</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers</article-title>. <source>J Nanobiotechnol</source> (<year>2021</year>) <volume>19</volume>(<issue>1</issue>):<fpage>59</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12951-021-00806-7</pub-id><pub-id pub-id-type="pmcid">PMC7905985</pub-id><pub-id pub-id-type="pmid">33632278</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mej&#237;a-M&#233;ndez</surname><given-names>JL</given-names></name><name name-style="western"><surname>Vazquez-Duhalt</surname><given-names>R</given-names></name><name name-style="western"><surname>Hern&#225;ndez</surname><given-names>LR</given-names></name><name name-style="western"><surname>S&#225;nchez-Arreola</surname><given-names>E</given-names></name><name name-style="western"><surname>Bach</surname><given-names>H</given-names></name></person-group>. <article-title>Virus-like particles: Fundamentals and biomedical applications</article-title>. <source>Int J Mol Sci</source> (<year>2022</year>) <volume>23</volume>(<issue>15</issue>):<elocation-id>8579</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms23158579</pub-id><pub-id pub-id-type="pmid">35955711</pub-id><pub-id pub-id-type="pmcid">PMC9369363</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tariq</surname><given-names>H</given-names></name><name name-style="western"><surname>Batool</surname><given-names>S</given-names></name><name name-style="western"><surname>Asif</surname><given-names>S</given-names></name><name name-style="western"><surname>Ali</surname><given-names>M</given-names></name><name name-style="western"><surname>Abbasi</surname><given-names>BH</given-names></name></person-group>. <article-title>Virus-like particles: Revolutionary platforms for developing vaccines against emerging infectious diseases</article-title>. <source>Front Microbiol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>790121</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmicb.2021.790121</pub-id><pub-id pub-id-type="pmid">35046918</pub-id><pub-id pub-id-type="pmcid">PMC8761975</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biela</surname><given-names>AP</given-names></name><name name-style="western"><surname>Naskalska</surname><given-names>A</given-names></name><name name-style="western"><surname>Fatehi</surname><given-names>F</given-names></name><name name-style="western"><surname>Twarock</surname><given-names>R</given-names></name><name name-style="western"><surname>Heddle</surname><given-names>JG</given-names></name></person-group>. <article-title>Programmable polymorphism of a virus-like particle</article-title>. <source>Commun Mater</source> (<year>2022</year>) <volume>3</volume>(<issue>1</issue>):<fpage>7</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s43246-022-00229-3</pub-id><pub-id pub-id-type="pmid">35284827</pub-id><pub-id pub-id-type="pmcid">PMC7612486</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donaldson</surname><given-names>B</given-names></name><name name-style="western"><surname>Lateef</surname><given-names>Z</given-names></name><name name-style="western"><surname>Walker</surname><given-names>GF</given-names></name><name name-style="western"><surname>Young</surname><given-names>SL</given-names></name><name name-style="western"><surname>Ward</surname><given-names>VK</given-names></name></person-group>. <article-title>Virus-like particle vaccines: Immunology and formulation for clinical translation</article-title>. <source>Expert Rev Vaccines</source> (<year>2018</year>) <volume>17</volume>(<issue>9</issue>):<page-range>833&#8211;49</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/14760584.2018.1516552</pub-id><pub-id pub-id-type="pmcid">PMC7103734</pub-id><pub-id pub-id-type="pmid">30173619</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lomonossoff</surname><given-names>GP</given-names></name><name name-style="western"><surname>Ponndorf</surname><given-names>D</given-names></name></person-group>. <article-title>Biotechnology approaches to modern vaccine design</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Bamford</surname><given-names>DH</given-names></name><name name-style="western"><surname>Zuckerman</surname><given-names>M</given-names></name></person-group>, editors. <source>Encyclopedia of virology</source>, <edition>4th ed</edition>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Academic Press</publisher-name> (<year>2021</year>). p. <page-range>662&#8211;70</page-range>.</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zepeda-Cervantes</surname><given-names>J</given-names></name><name name-style="western"><surname>Ram&#237;rez-Jarqu&#237;n</surname><given-names>JO</given-names></name><name name-style="western"><surname>Vaca</surname><given-names>L</given-names></name></person-group>. <article-title>Interaction between virus-like particles (Vlps) and pattern recognition receptors (Prrs) from dendritic cells (Dcs): Toward better engineering of vlps</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>1100</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2020.01100</pub-id><pub-id pub-id-type="pmid">32582186</pub-id><pub-id pub-id-type="pmcid">PMC7297083</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chavda</surname><given-names>VP</given-names></name><name name-style="western"><surname>Bezbaruah</surname><given-names>R</given-names></name><name name-style="western"><surname>Athalye</surname><given-names>M</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>PK</given-names></name><name name-style="western"><surname>Chhipa</surname><given-names>AS</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Replicating viral vector-based vaccines for covid-19: Potential avenue in vaccination arena</article-title>. <source>Viruses</source> (<year>2022</year>) <volume>14</volume>(<issue>4</issue>). doi:&#160;<pub-id pub-id-type="doi">10.3390/v14040759</pub-id><pub-id pub-id-type="pmcid">PMC9025561</pub-id><pub-id pub-id-type="pmid">35458489</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Travieso</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Mahesh</surname><given-names>S</given-names></name><name name-style="western"><surname>Mello</surname><given-names>JDFRE</given-names></name><name name-style="western"><surname>Blasi</surname><given-names>M</given-names></name></person-group>. <article-title>The use of viral vectors in vaccine development</article-title>. <source>NPJ Vaccines</source> (<year>2022</year>) <volume>7</volume>(<issue>1</issue>):<fpage>75</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-022-00503-y</pub-id><pub-id pub-id-type="pmid">35787629</pub-id><pub-id pub-id-type="pmcid">PMC9253346</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rauch</surname><given-names>S</given-names></name><name name-style="western"><surname>Jasny</surname><given-names>E</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>KE</given-names></name><name name-style="western"><surname>Petsch</surname><given-names>B</given-names></name></person-group>. <article-title>New vaccine technologies to combat outbreak situations</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>1963</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.01963</pub-id><pub-id pub-id-type="pmid">30283434</pub-id><pub-id pub-id-type="pmcid">PMC6156540</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Maruggi</surname><given-names>G</given-names></name><name name-style="western"><surname>Shan</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name></person-group>. <article-title>Advances in mrna vaccines for infectious diseases</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>594</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00594</pub-id><pub-id pub-id-type="pmid">30972078</pub-id><pub-id pub-id-type="pmcid">PMC6446947</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JW</given-names></name><name name-style="western"><surname>Lagniton</surname><given-names>PNP</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>RH</given-names></name></person-group>. <article-title>Mrna vaccines for covid-19: What, why and how</article-title>. <source>Int J Biol Sci</source> (<year>2021</year>) <volume>17</volume>(<issue>6</issue>):<page-range>1446&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.7150/ijbs.59233</pub-id><pub-id pub-id-type="pmcid">PMC8071766</pub-id><pub-id pub-id-type="pmid">33907508</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosa</surname><given-names>SS</given-names></name><name name-style="western"><surname>Prazeres</surname><given-names>DMF</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>AM</given-names></name><name name-style="western"><surname>Marques</surname><given-names>MPC</given-names></name></person-group>. <article-title>Mrna vaccines manufacturing: Challenges and bottlenecks</article-title>. <source>Vaccine</source> (<year>2021</year>) <volume>39</volume>(<issue>16</issue>):<page-range>2190&#8211;200</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.038</pub-id><pub-id pub-id-type="pmcid">PMC7987532</pub-id><pub-id pub-id-type="pmid">33771389</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Eygeris</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M</given-names></name><name name-style="western"><surname>Sahay</surname><given-names>G</given-names></name></person-group>. <article-title>Self-assembled mrna vaccines</article-title>. <source>Adv Drug Delivery Rev</source> (<year>2021</year>) <volume>170</volume>:<fpage>83</fpage>&#8211;<lpage>112</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.addr.2020.12.014</pub-id><pub-id pub-id-type="pmcid">PMC7837307</pub-id><pub-id pub-id-type="pmid">33400957</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domazet-Lo&#353;o</surname><given-names>T</given-names></name></person-group>. <article-title>Mrna vaccines: Why is the biology of retroposition ignored</article-title>? <source>Genes (Basel)</source> (<year>2022</year>) <volume>13</volume>(<issue>5</issue>). doi:&#160;<pub-id pub-id-type="doi">10.3390/genes13050719</pub-id><pub-id pub-id-type="pmcid">PMC9141755</pub-id><pub-id pub-id-type="pmid">35627104</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barda</surname><given-names>N</given-names></name><name name-style="western"><surname>Dagan</surname><given-names>N</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C</given-names></name><name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></name><name name-style="western"><surname>Kohane</surname><given-names>IS</given-names></name><etal/></person-group>. <article-title>Effectiveness of a third dose of the Bnt162b2 mrna covid-19 vaccine for preventing severe outcomes in Israel: An observational study</article-title>. <source>Lancet</source> (<year>2021</year>) <volume>398</volume>(<issue>10316</issue>):<page-range>2093&#8211;100</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0140-6736(21)02249-2</pub-id><pub-id pub-id-type="pmcid">PMC8555967</pub-id><pub-id pub-id-type="pmid">34756184</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>P</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>MR</given-names></name><name name-style="western"><surname>Chemaitelly</surname><given-names>H</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>HM</given-names></name><name name-style="western"><surname>Benslimane</surname><given-names>FM</given-names></name><name name-style="western"><surname>Al Khatib</surname><given-names>HA</given-names></name><etal/></person-group>. <article-title>Bnt162b2 and mrna-1273 covid-19 vaccine effectiveness against the sars-Cov-2 delta variant in Qatar</article-title>. <source>Nat Med</source> (<year>2021</year>) <volume>27</volume>(<issue>12</issue>):<page-range>2136&#8211;43</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41591-021-01583-4</pub-id><pub-id pub-id-type="pmid">34728831</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walter</surname><given-names>EB</given-names></name><name name-style="western"><surname>Talaat</surname><given-names>KR</given-names></name><name name-style="western"><surname>Sabharwal</surname><given-names>C</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><name name-style="western"><surname>Paulsen</surname><given-names>GC</given-names></name><etal/></person-group>. <article-title>Evaluation of the Bnt162b2 covid-19 vaccine in children 5 to 11 years of age</article-title>. <source>N Engl J Med</source> (<year>2022</year>) <volume>386</volume>(<issue>1</issue>):<fpage>35</fpage>&#8211;<lpage>46</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2116298</pub-id><pub-id pub-id-type="pmid">34752019</pub-id><pub-id pub-id-type="pmcid">PMC8609605</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name></person-group>. <article-title>Next-generation nonviral vectors for mrna vaccine delivery</article-title>. <source>Macromol Chem Phys</source> (<year>2022</year>) <volume>223</volume>(<issue>5</issue>):<elocation-id>2100443</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1002/macp.202100443</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esteban</surname><given-names>I</given-names></name><name name-style="western"><surname>Pastor-Qui&#241;ones</surname><given-names>C</given-names></name><name name-style="western"><surname>Usero</surname><given-names>L</given-names></name><name name-style="western"><surname>Plana</surname><given-names>M</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>F</given-names></name><name name-style="western"><surname>Leal</surname><given-names>L</given-names></name></person-group>. <article-title>In the era of mrna vaccines, is there any hope for hiv functional cure</article-title>? <source>Viruses</source> (<year>2021</year>) <volume>13</volume>(<issue>3</issue>). doi:&#160;<pub-id pub-id-type="doi">10.3390/v13030501</pub-id><pub-id pub-id-type="pmcid">PMC8003302</pub-id><pub-id pub-id-type="pmid">33803790</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Y-N</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y-L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H-B</given-names></name><etal/></person-group>. <article-title>Cationic lipid-assisted nanoparticles for delivery of mrna cancer vaccine</article-title>. <source>Biomater Sci</source> (<year>2018</year>) <volume>6</volume>(<issue>11</issue>):<page-range>3009&#8211;18</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1039/C8BM00908B</pub-id><pub-id pub-id-type="pmid">30264063</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pippa</surname><given-names>N</given-names></name><name name-style="western"><surname>Gazouli</surname><given-names>M</given-names></name><name name-style="western"><surname>Pispas</surname><given-names>S</given-names></name></person-group>. <article-title>Recent advances and future perspectives in polymer-based nanovaccines</article-title>. <source>Vaccines (Basel)</source> (<year>2021</year>) <volume>9</volume>(<issue>6</issue>). doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9060558</pub-id><pub-id pub-id-type="pmcid">PMC8226647</pub-id><pub-id pub-id-type="pmid">34073648</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Milovanovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Arsenijevic</surname><given-names>A</given-names></name><name name-style="western"><surname>Milovanovic</surname><given-names>J</given-names></name><name name-style="western"><surname>Kanjevac</surname><given-names>T</given-names></name><name name-style="western"><surname>Arsenijevic</surname><given-names>N</given-names></name></person-group>. <article-title>Chapter 14 - nanoparticles in antiviral therapy</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Grumezescu</surname><given-names>AM</given-names></name></person-group>, editor. <source>Antimicrobial nanoarchitectonics</source>. <publisher-name>Elsevier</publisher-name> (<year>2017</year>). p. <fpage>383</fpage>&#8211;<lpage>410</lpage>. doi: <pub-id pub-id-type="doi">10.1016/B978-0-323-52733-0.00014-8</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rehm</surname><given-names>BHA</given-names></name></person-group>. <article-title>Bioengineering towards self-assembly of particulate vaccines</article-title>. <source>Curr Opin Biotechnol</source> (<year>2017</year>) <volume>48</volume>:<fpage>42</fpage>&#8211;<lpage>53</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.copbio.2017.03.018</pub-id><pub-id pub-id-type="pmid">28365472</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K</given-names></name></person-group>. <article-title>Polymer-based nanomaterials and applications for vaccines and drugs</article-title>. <source>Polymers (Basel)</source> (<year>2018</year>) <volume>10</volume>(<issue>1</issue>). doi:&#160;<pub-id pub-id-type="doi">10.3390/polym10010031</pub-id><pub-id pub-id-type="pmcid">PMC6415012</pub-id><pub-id pub-id-type="pmid">30966075</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>S</given-names></name><name name-style="western"><surname>Fu</surname><given-names>D</given-names></name><name name-style="western"><surname>Utupova</surname><given-names>A</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Applications of polymer-based nanoparticles in vaccine field</article-title>. <source>Nanotechnol Rev</source> (<year>2019</year>) <volume>8</volume>(<issue>1</issue>):<page-range>143&#8211;55</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1515/ntrev-2019-0014</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabado</surname><given-names>RL</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></name></person-group>. <article-title>Directing dendritic cell immunotherapy towards successful cancer treatment</article-title>. <source>Immunotherapy</source> (<year>2010</year>) <volume>2</volume>(<issue>1</issue>):<fpage>37</fpage>&#8211;<lpage>56</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.2217/imt.09.43</pub-id><pub-id pub-id-type="pmid">20473346</pub-id><pub-id pub-id-type="pmcid">PMC2867472</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sartorius</surname><given-names>R</given-names></name><name name-style="western"><surname>Trovato</surname><given-names>M</given-names></name><name name-style="western"><surname>Manco</surname><given-names>R</given-names></name><name name-style="western"><surname>D&#8217;Apice</surname><given-names>L</given-names></name><name name-style="western"><surname>De Berardinis</surname><given-names>P</given-names></name></person-group>. <article-title>Exploiting viral sensing mediated by toll-like receptors to design innovative vaccines</article-title>. <source>NPJ Vaccines</source> (<year>2021</year>) <volume>6</volume>(<issue>1</issue>):<fpage>127</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-021-00391-8</pub-id><pub-id pub-id-type="pmid">34711839</pub-id><pub-id pub-id-type="pmcid">PMC8553822</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keikha</surname><given-names>R</given-names></name><name name-style="western"><surname>Daliri</surname><given-names>K</given-names></name><name name-style="western"><surname>Jebali</surname><given-names>A</given-names></name></person-group>. <article-title>The use of nanobiotechnology in immunology and vaccination</article-title>. <source>Vaccines (Basel)</source> (<year>2021</year>) <volume>9</volume>(<issue>2</issue>). doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9020074</pub-id><pub-id pub-id-type="pmcid">PMC7910821</pub-id><pub-id pub-id-type="pmid">33494441</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanaparthy</surname><given-names>R</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>G</given-names></name><name name-style="western"><surname>Vasireddy</surname><given-names>D</given-names></name><name name-style="western"><surname>Atluri</surname><given-names>P</given-names></name></person-group>. <article-title>Review of covid-19 viral vector-based vaccines and covid-19 variants</article-title>. <source>Infez Med</source> (<year>2021</year>) <volume>29</volume>(<issue>3</issue>):<page-range>328&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.53854/liim-2903-3</pub-id><pub-id pub-id-type="pmcid">PMC8805485</pub-id><pub-id pub-id-type="pmid">35146337</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humphreys</surname><given-names>IR</given-names></name><name name-style="western"><surname>Sebastian</surname><given-names>S</given-names></name></person-group>. <article-title>Novel viral vectors in infectious diseases</article-title>. <source>Immunology</source> (<year>2018</year>) <volume>153</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>9</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/imm.12829</pub-id><pub-id pub-id-type="pmid">28869761</pub-id><pub-id pub-id-type="pmcid">PMC5721250</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>CS</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>ES</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Farina</surname><given-names>EM</given-names></name><name name-style="western"><surname>Yan</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine</article-title>. <source>Genes Dis</source> (<year>2017</year>) <volume>4</volume>(<issue>2</issue>):<fpage>43</fpage>&#8211;<lpage>63</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.gendis.2017.04.001</pub-id><pub-id pub-id-type="pmid">28944281</pub-id><pub-id pub-id-type="pmcid">PMC5609467</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>S</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Viral vector vaccine development and application during the covid-19 pandemic</article-title>. <source>Microorganisms</source> (<year>2022</year>) <volume>10</volume>(<issue>7</issue>):<elocation-id>1450</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/microorganisms10071450</pub-id><pub-id pub-id-type="pmid">35889169</pub-id><pub-id pub-id-type="pmcid">PMC9317404</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>HY</given-names></name><name name-style="western"><surname>Liao</surname><given-names>HY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SW</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>CW</given-names></name><name name-style="western"><surname>Shahed-Al-Mahmud</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Vaccination with sars-Cov-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models</article-title>. <source>Sci Transl Med</source> (<year>2022</year>) <volume>14</volume>(<issue>639</issue>):<elocation-id>eabm0899</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.abm0899</pub-id><pub-id pub-id-type="pmid">35230146</pub-id><pub-id pub-id-type="pmcid">PMC9802656</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hogan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Pardi</surname><given-names>N</given-names></name></person-group>. <article-title>Mrna vaccines in the covid-19 pandemic and beyond</article-title>. <source>Annu Rev Med</source> (<year>2022</year>) <volume>73</volume>:<fpage>17</fpage>&#8211;<lpage>39</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1146/annurev-med-042420-112725</pub-id><pub-id pub-id-type="pmid">34669432</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heine</surname><given-names>A</given-names></name><name name-style="western"><surname>Juranek</surname><given-names>S</given-names></name><name name-style="western"><surname>Brossart</surname><given-names>P</given-names></name></person-group>. <article-title>Clinical and immunological effects of mrna vaccines in malignant diseases</article-title>. <source>Mol Cancer</source> (<year>2021</year>) <volume>20</volume>(<issue>1</issue>):<fpage>52</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12943-021-01339-1</pub-id><pub-id pub-id-type="pmid">33722265</pub-id><pub-id pub-id-type="pmcid">PMC7957288</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rijkers</surname><given-names>GT</given-names></name><name name-style="western"><surname>Weterings</surname><given-names>N</given-names></name><name name-style="western"><surname>Obregon-Henao</surname><given-names>A</given-names></name><name name-style="western"><surname>Lepolder</surname><given-names>M</given-names></name><name name-style="western"><surname>Dutt</surname><given-names>TS</given-names></name><name name-style="western"><surname>van Overveld</surname><given-names>FJ</given-names></name><etal/></person-group>. <article-title>Antigen presentation of mrna-based and virus-vectored sars-Cov-2 vaccines</article-title>. <source>Vaccines (Basel)</source> (<year>2021</year>) <volume>9</volume>(<issue>8</issue>). doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9080848</pub-id><pub-id pub-id-type="pmcid">PMC8402319</pub-id><pub-id pub-id-type="pmid">34451973</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bettini</surname><given-names>E</given-names></name><name name-style="western"><surname>Locci</surname><given-names>M</given-names></name></person-group>. <article-title>Sars-Cov-2 mrna vaccines: Immunological mechanism and beyond</article-title>. <source>Vaccines (Basel)</source> (<year>2021</year>) <volume>9</volume>(<issue>2</issue>). doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9020147</pub-id><pub-id pub-id-type="pmcid">PMC7918810</pub-id><pub-id pub-id-type="pmid">33673048</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>E</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Advances in covid-19 mrna vaccine development</article-title>. <source>Signal Transduct Target Ther</source> (<year>2022</year>) <volume>7</volume>(<issue>1</issue>):<fpage>94</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41392-022-00950-y</pub-id><pub-id pub-id-type="pmid">35322018</pub-id><pub-id pub-id-type="pmcid">PMC8940982</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linares-Fern&#225;ndez</surname><given-names>S</given-names></name><name name-style="western"><surname>Lacroix</surname><given-names>C</given-names></name><name name-style="western"><surname>Exposito</surname><given-names>J-Y</given-names></name><name name-style="western"><surname>Verrier</surname><given-names>B</given-names></name></person-group>. <article-title>Tailoring mrna vaccine to balance Innate/Adaptive immune response</article-title>. <source>Trends Mol Med</source> (<year>2020</year>) <volume>26</volume>(<issue>3</issue>):<page-range>311&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.molmed.2019.10.002</pub-id><pub-id pub-id-type="pmid">31699497</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nitika</surname></name><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Hui</surname><given-names>A-M</given-names></name></person-group>. <article-title>The development of mrna vaccines for infectious diseases: Recent updates</article-title>. <source>Infect Drug Resistance</source> (<year>2021</year>) <volume>14</volume>:<page-range>5271&#8211;85</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2147/idr.s341694</pub-id><pub-id pub-id-type="pmcid">PMC8668227</pub-id><pub-id pub-id-type="pmid">34916811</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>T</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X</given-names></name></person-group>. <article-title>Mrna vaccine development for emerging animal and zoonotic diseases</article-title>. <source>Viruses</source> (<year>2022</year>) <volume>14</volume>(<issue>2</issue>):<elocation-id>401</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/v14020401</pub-id><pub-id pub-id-type="pmid">35215994</pub-id><pub-id pub-id-type="pmcid">PMC8877136</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>N</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>KA</given-names></name></person-group>. <article-title>Mrna vaccines for infectious diseases: Principles, delivery and clinical translation</article-title>. <source>Nat Rev Drug Discovery</source> (<year>2021</year>) <volume>20</volume>(<issue>11</issue>):<page-range>817&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41573-021-00283-5</pub-id><pub-id pub-id-type="pmcid">PMC8386155</pub-id><pub-id pub-id-type="pmid">34433919</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowalski</surname><given-names>PS</given-names></name><name name-style="western"><surname>Rudra</surname><given-names>A</given-names></name><name name-style="western"><surname>Miao</surname><given-names>L</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>DG</given-names></name></person-group>. <article-title>Delivering the messenger: Advances in technologies for therapeutic mrna delivery</article-title>. <source>Mol Ther</source> (<year>2019</year>) <volume>27</volume>(<issue>4</issue>):<page-range>710&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ymthe.2019.02.012</pub-id><pub-id pub-id-type="pmcid">PMC6453548</pub-id><pub-id pub-id-type="pmid">30846391</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vu</surname><given-names>MN</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>HG</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>AK</given-names></name></person-group>. <article-title>Current and future nanoparticle vaccines for covid-19</article-title>. <source>EBioMedicine</source> (<year>2021</year>) <volume>74</volume>:<elocation-id>103699</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103699</pub-id><pub-id pub-id-type="pmid">34801965</pub-id><pub-id pub-id-type="pmcid">PMC8602808</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lambricht</surname><given-names>L</given-names></name><name name-style="western"><surname>Peres</surname><given-names>C</given-names></name><name name-style="western"><surname>Florindo</surname><given-names>H</given-names></name><name name-style="western"><surname>Pr&#233;at</surname><given-names>V</given-names></name><name name-style="western"><surname>Vandermeulen</surname><given-names>G</given-names></name></person-group>. <article-title>Chapter ten - polymer-based nanoparticles as modern vaccine delivery systems</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Skwarczynski</surname><given-names>M</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I</given-names></name></person-group>, editors. <source>Micro and nanotechnology in vaccine development</source>. <publisher-name>William Andrew Publishing</publisher-name> (<year>2017</year>). p. <fpage>185</fpage>&#8211;<lpage>203</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/B978-0-323-39981-4.00010-5</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>R</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Ting</surname><given-names>K</given-names></name><name name-style="western"><surname>Soo</surname><given-names>C</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z</given-names></name></person-group>. <article-title>Current development of biodegradable polymeric materials for biomedical applications</article-title>. <source>Drug Design Dev Ther</source> (<year>2018</year>) <volume>12</volume>:<page-range>3117&#8211;45</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2147/dddt.s165440</pub-id><pub-id pub-id-type="pmcid">PMC6161720</pub-id><pub-id pub-id-type="pmid">30288019</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bose</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Paulmurugan</surname><given-names>R</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Koh</surname><given-names>WG</given-names></name><etal/></person-group>. <article-title>Biodegradable polymers for modern vaccine development</article-title>. <source>J Ind Eng Chem</source> (<year>2019</year>) <volume>77</volume>:<fpage>12</fpage>&#8211;<lpage>24</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jiec.2019.04.044</pub-id><pub-id pub-id-type="pmid">32288512</pub-id><pub-id pub-id-type="pmcid">PMC7129903</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miu</surname><given-names>DM</given-names></name><name name-style="western"><surname>Eremia</surname><given-names>MC</given-names></name><name name-style="western"><surname>Moscovici</surname><given-names>M</given-names></name></person-group>. <article-title>Polyhydroxyalkanoates (Phas) as biomaterials in tissue engineering: Production, isolation, characterization</article-title>. <source>Mater (Basel)</source> (<year>2022</year>) <volume>15</volume>(<issue>4</issue>). doi:&#160;<pub-id pub-id-type="doi">10.3390/ma15041410</pub-id><pub-id pub-id-type="pmcid">PMC8875380</pub-id><pub-id pub-id-type="pmid">35207952</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JW</given-names></name><name name-style="western"><surname>Parlane</surname><given-names>NA</given-names></name><name name-style="western"><surname>Wedlock</surname><given-names>DN</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>BH</given-names></name></person-group>. <article-title>Bioengineering a bacterial pathogen to assemble its own particulate vaccine capable of inducing cellular immunity</article-title>. <source>Sci Rep</source> (<year>2017</year>) <volume>7</volume>:<elocation-id>41607</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1038/srep41607</pub-id><pub-id pub-id-type="pmid">28150705</pub-id><pub-id pub-id-type="pmcid">PMC5288705</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzaga</surname><given-names>ZJC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Lehoux</surname><given-names>M</given-names></name><name name-style="western"><surname>Segura</surname><given-names>M</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>BHA</given-names></name></person-group>. <article-title>Engineering antigens to assemble into polymer particle vaccines for prevention of streptococcus suis infection</article-title>. <source>Vaccines</source> (<year>2021</year>) <volume>9</volume>(<issue>12</issue>):<elocation-id>1386</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9121386</pub-id><pub-id pub-id-type="pmid">34960132</pub-id><pub-id pub-id-type="pmcid">PMC8709461</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evert</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>McConville</surname><given-names>R</given-names></name><name name-style="western"><surname>Steel</surname><given-names>RWJ</given-names></name><name name-style="western"><surname>Healer</surname><given-names>J</given-names></name><name name-style="western"><surname>Boddey</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Epitope-coated polymer particles elicit neutralising antibodies against plasmodium falciparum sporozoites</article-title>. <source>NPJ Vaccines</source> (<year>2021</year>) <volume>6</volume>(<issue>1</issue>):<fpage>141</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-021-00408-2</pub-id><pub-id pub-id-type="pmid">34845267</pub-id><pub-id pub-id-type="pmcid">PMC8630014</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Evert</surname><given-names>B</given-names></name><name name-style="western"><surname>Adeniyi</surname><given-names>A</given-names></name><name name-style="western"><surname>Salla-Martret</surname><given-names>M</given-names></name><name name-style="western"><surname>Lua</surname><given-names>LH-L</given-names></name><name name-style="western"><surname>Ozberk</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Ambient temperature stable, scalable covid-19 polymer particle vaccines induce protective immunity</article-title>. <source>Adv Healthcare Mater</source> (<year>2022</year>) <volume>11</volume>(<issue>3</issue>):<elocation-id>2102089</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1002/adhm.202102089</pub-id><pub-id pub-id-type="pmcid">PMC8652985</pub-id><pub-id pub-id-type="pmid">34716678</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzaga</surname><given-names>ZJC</given-names></name><name name-style="western"><surname>Merakou</surname><given-names>C</given-names></name><name name-style="western"><surname>DiGiandomenico</surname><given-names>A</given-names></name><name name-style="western"><surname>Priebe</surname><given-names>GP</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>BHA</given-names></name></person-group>. <article-title>A pseudomonas aeruginosa-derived particulate vaccine protects against p. aeruginosa infection</article-title>. <source>Vaccines</source> (<year>2021</year>) <volume>9</volume>(<issue>7</issue>):<elocation-id>803</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9070803</pub-id><pub-id pub-id-type="pmid">34358220</pub-id><pub-id pub-id-type="pmcid">PMC8309987</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzaga</surname><given-names>ZJC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>BH</given-names></name></person-group>. <article-title>Intranasal delivery of antigen-coated polymer particles protects against pseudomonas aeruginosa infection</article-title>. <source>ACS Infect Dis</source> (<year>2022</year>) <volume>8</volume>(<issue>4</issue>):<page-range>744&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acsinfecdis.1c00434</pub-id><pub-id pub-id-type="pmid">35238554</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parlane</surname><given-names>NA</given-names></name><name name-style="western"><surname>Grage</surname><given-names>K</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JW</given-names></name><name name-style="western"><surname>Buddle</surname><given-names>BM</given-names></name><name name-style="western"><surname>Denis</surname><given-names>M</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>BHA</given-names></name></person-group>. <article-title>Production of a particulate hepatitis c vaccine candidate by an engineered lactococcus lactis strain</article-title>. <source>Appl Environ Microbiol</source> (<year>2011</year>) <volume>77</volume>(<issue>24</issue>):<page-range>8516&#8211;22</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/AEM.06420-11</pub-id><pub-id pub-id-type="pmcid">PMC3233089</pub-id><pub-id pub-id-type="pmid">21984246</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parlane</surname><given-names>NA</given-names></name><name name-style="western"><surname>Grage</surname><given-names>K</given-names></name><name name-style="western"><surname>Mifune</surname><given-names>J</given-names></name><name name-style="western"><surname>Basaraba</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Wedlock</surname><given-names>DN</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>BHA</given-names></name><etal/></person-group>. <article-title>Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis</article-title>. <source>Clin Vaccine Immunol</source> (<year>2012</year>) <volume>19</volume>(<issue>1</issue>):<fpage>37</fpage>&#8211;<lpage>44</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CVI.05505-11</pub-id><pub-id pub-id-type="pmid">22072720</pub-id><pub-id pub-id-type="pmcid">PMC3255957</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Miro</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Noda</surname><given-names>L</given-names></name><name name-style="western"><surname>Fari&#241;as-Medina</surname><given-names>M</given-names></name><name name-style="western"><surname>Garc&#237;a-Rivera</surname><given-names>D</given-names></name><name name-style="western"><surname>V&#233;rez-Bencomo</surname><given-names>V</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>BHA</given-names></name></person-group>. <article-title>Self-assembled particulate psaa as vaccine against streptococcus pneumoniae infection</article-title>. <source>Heliyon</source> (<year>2017</year>) <volume>3</volume>(<issue>4</issue>):<elocation-id>e00291</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.heliyon.2017.e00291</pub-id><pub-id pub-id-type="pmid">28435909</pub-id><pub-id pub-id-type="pmcid">PMC5390691</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Mir&#243;</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Noda</surname><given-names>LM</given-names></name><name name-style="western"><surname>Fari&#241;as-Medina</surname><given-names>M</given-names></name><name name-style="western"><surname>Cedr&#233;-Marrero</surname><given-names>B</given-names></name><name name-style="western"><surname>Madariaga-Zarza</surname><given-names>S</given-names></name><name name-style="western"><surname>Zayas-Vignier</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Bioengineered polyester beads Co-displaying protein and carbohydrate-based antigens induce protective immunity against bacterial infection</article-title>. <source>Sci Rep</source> (<year>2018</year>) <volume>8</volume>(<issue>1</issue>):<fpage>1888</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-018-20205-7</pub-id><pub-id pub-id-type="pmid">29382864</pub-id><pub-id pub-id-type="pmcid">PMC5789850</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheffee</surname><given-names>NS</given-names></name><name name-style="western"><surname>Rubio-Reyes</surname><given-names>P</given-names></name><name name-style="western"><surname>Mirabal</surname><given-names>M</given-names></name><name name-style="western"><surname>Calero</surname><given-names>R</given-names></name><name name-style="western"><surname>Carrillo-Calvet</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Engineered mycobacterium tuberculosis antigen assembly into core-shell nanobeads for diagnosis of tuberculosis</article-title>. <source>Nanomed: Nanotechnol Biol Med</source> (<year>2021</year>) <volume>34</volume>:<elocation-id>102374</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.nano.2021.102374</pub-id><pub-id pub-id-type="pmid">33675981</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Quan</surname><given-names>DH</given-names></name><name name-style="western"><surname>Sam</surname><given-names>G</given-names></name><name name-style="western"><surname>Ozberk</surname><given-names>V</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XT</given-names></name><name name-style="western"><surname>Halfmann</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Assembly of immunogenic protein particles toward advanced synthetic vaccines</article-title>. <source>Small</source> (<year>2022</year>). doi: <pub-id pub-id-type="doi">10.1002/smll.202205819</pub-id><pub-id pub-id-type="pmid">36564365</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name></person-group>. <article-title>Eliciting b cell immunity against infectious diseases using nanovaccines</article-title>. <source>Nat Nanotechnol</source> (<year>2021</year>) <volume>16</volume>(<issue>1</issue>):<fpage>16</fpage>&#8211;<lpage>24</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41565-020-00790-3</pub-id><pub-id pub-id-type="pmid">33199883</pub-id><pub-id pub-id-type="pmcid">PMC7855692</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></name><name name-style="western"><surname>Arunachalam P</surname><given-names>S</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name></person-group>. <article-title>Emerging concepts in the science of vaccine adjuvants</article-title>. <source>Nat Rev Drug Discovery</source> (<year>2021</year>) <volume>20</volume>(<issue>6</issue>):<page-range>454&#8211;75</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id><pub-id pub-id-type="pmid">33824489</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>A</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J</given-names></name><name name-style="western"><surname>Brar</surname><given-names>D</given-names></name><name name-style="western"><surname>Salunke</surname><given-names>DB</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name></person-group>. <article-title>Toll-like receptor (Tlr) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics</article-title>. <source>Curr Opin Chem Biol</source> (<year>2022</year>) <volume>70</volume>:<elocation-id>102172</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cbpa.2022.102172</pub-id><pub-id pub-id-type="pmid">35785601</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>PK</given-names></name><name name-style="western"><surname>Dmitriev</surname><given-names>IP</given-names></name><name name-style="western"><surname>Kashentseva</surname><given-names>EA</given-names></name><name name-style="western"><surname>Raes</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SW</given-names></name><etal/></person-group>. <article-title>Development of an adenovirus vector vaccine platform for targeting dendritic cells</article-title>. <source>Cancer Gene Ther</source> (<year>2018</year>) <volume>25</volume>(<issue>1</issue>):<fpage>27</fpage>&#8211;<lpage>38</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41417-017-0002-1</pub-id><pub-id pub-id-type="pmid">29242639</pub-id><pub-id pub-id-type="pmcid">PMC5972836</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosca</surname><given-names>F</given-names></name><name name-style="western"><surname>Tritto</surname><given-names>E</given-names></name><name name-style="western"><surname>Muzzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Monaci</surname><given-names>E</given-names></name><name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Iavarone</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Molecular and cellular signatures of human vaccine adjuvants</article-title>. <source>Proc Natl Acad Sci</source> (<year>2008</year>) <volume>105</volume>(<issue>30</issue>):<page-range>10501&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0804699105</pub-id><pub-id pub-id-type="pmcid">PMC2483233</pub-id><pub-id pub-id-type="pmid">18650390</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Backlund</surname><given-names>CM</given-names></name><name name-style="western"><surname>Holden</surname><given-names>RL</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>KD</given-names></name><name name-style="western"><surname>Garafola</surname><given-names>D</given-names></name><name name-style="western"><surname>Farquhar</surname><given-names>C</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>NK</given-names></name><etal/></person-group>. <article-title>Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity</article-title>. <source>Proc Natl Acad Sci</source> (<year>2022</year>) <volume>119</volume>(<issue>32</issue>):<elocation-id>e2204078119</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.2204078119</pub-id><pub-id pub-id-type="pmid">35914154</pub-id><pub-id pub-id-type="pmcid">PMC9371699</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>S</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Vale</surname><given-names>N</given-names></name></person-group>. <article-title>Combination of cell-penetrating peptides with nanoparticles for therapeutic application: A review</article-title>. <source>Biomolecules</source> (<year>2019</year>) <volume>9</volume>(<issue>1</issue>):<elocation-id>22</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/biom9010022</pub-id><pub-id pub-id-type="pmid">30634689</pub-id><pub-id pub-id-type="pmcid">PMC6359287</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P</given-names></name></person-group>. <article-title>Membrane internalization mechanisms and design strategies of arginine-rich cell-penetrating peptides</article-title>. <source>Int J Mol Sci</source> (<year>2022</year>) <volume>23</volume>(<issue>16</issue>):<elocation-id>9038</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms23169038</pub-id><pub-id pub-id-type="pmid">36012300</pub-id><pub-id pub-id-type="pmcid">PMC9409441</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>T</given-names></name><name name-style="western"><surname>Xin</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Human dendritic cell targeting peptide can be targeted to porcine dendritic cells to improve antigen capture efficiency to stimulate stronger immune response</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>950597</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.950597</pub-id><pub-id pub-id-type="pmid">36059519</pub-id><pub-id pub-id-type="pmcid">PMC9437479</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gou</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/Il-21 axis</article-title>. <source>Theranostics</source> (<year>2021</year>) <volume>11</volume>(<issue>15</issue>):<fpage>7308</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.7150/thno.56406</pub-id><pub-id pub-id-type="pmid">34158852</pub-id><pub-id pub-id-type="pmcid">PMC8210616</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy</article-title>. <source>Oncotarget</source> (<year>2016</year>) <volume>7</volume>(<issue>26</issue>):<fpage>40437</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.18632/oncotarget.9624</pub-id><pub-id pub-id-type="pmid">27250027</pub-id><pub-id pub-id-type="pmcid">PMC5130018</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ojha</surname><given-names>R</given-names></name><name name-style="western"><surname>Prajapati</surname><given-names>VK</given-names></name></person-group>. <article-title>Cognizance of posttranslational modifications in vaccines: A way to enhanced immunogenicity</article-title>. <source>J Cell Physiol</source> (<year>2021</year>) <volume>236</volume>(<issue>12</issue>):<page-range>8020&#8211;34</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/jcp.30483</pub-id><pub-id pub-id-type="pmcid">PMC8427110</pub-id><pub-id pub-id-type="pmid">34170014</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macek</surname><given-names>B</given-names></name><name name-style="western"><surname>Forchhammer</surname><given-names>K</given-names></name><name name-style="western"><surname>Hardouin</surname><given-names>J</given-names></name><name name-style="western"><surname>Weber-Ban</surname><given-names>E</given-names></name><name name-style="western"><surname>Grangeasse</surname><given-names>C</given-names></name><name name-style="western"><surname>Mijakovic</surname><given-names>I</given-names></name></person-group>. <article-title>Protein post-translational modifications in bacteria</article-title>. <source>Nat Rev Microbiol</source> (<year>2019</year>) <volume>17</volume>(<issue>11</issue>):<page-range>651&#8211;64</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41579-019-0243-0</pub-id><pub-id pub-id-type="pmid">31485032</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosano</surname><given-names>GL</given-names></name><name name-style="western"><surname>Ceccarelli</surname><given-names>EA</given-names></name></person-group>. <article-title>Recombinant protein expression in escherichia coli: Advances and challenges</article-title>. <source>Front Microbiol</source> (<year>2014</year>) <volume>5</volume>:<elocation-id>172/BIBTEX</elocation-id>(<issue>APR</issue>). doi:&#160;<pub-id pub-id-type="doi">10.3389/FMICB.2014.00172/BIBTEX</pub-id><pub-id pub-id-type="pmid">24860555</pub-id><pub-id pub-id-type="pmcid">PMC4029002</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nascimento</surname><given-names>IP</given-names></name><name name-style="western"><surname>Leite</surname><given-names>LCC</given-names></name></person-group>. <article-title>Recombinant vaccines and the development of new vaccine strategies</article-title>. <source>Braz J Med Biol Res</source> (<year>2012</year>) <volume>45</volume>(<issue>12</issue>):<fpage>1102</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1590/S0100-879X2012007500142</pub-id><pub-id pub-id-type="pmid">22948379</pub-id><pub-id pub-id-type="pmcid">PMC3854212</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meldal</surname><given-names>M</given-names></name><name name-style="western"><surname>Schoffelen</surname><given-names>S</given-names></name></person-group>. <article-title>Recent advances in covalent, site-specific protein immobilization</article-title>. <source>F1000Research</source> (<year>2016</year>) <volume>5</volume>. doi:&#160;<pub-id pub-id-type="doi">10.12688/F1000RESEARCH.9002.1</pub-id><pub-id pub-id-type="pmcid">PMC5022707</pub-id><pub-id pub-id-type="pmid">27785356</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Boer</surname><given-names>E</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>P</given-names></name><name name-style="western"><surname>Bonte</surname><given-names>E</given-names></name><name name-style="western"><surname>Krijgsveldt</surname><given-names>J</given-names></name><name name-style="western"><surname>Katsantoni</surname><given-names>E</given-names></name><name name-style="western"><surname>Heckt</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and transgenic mice</article-title>. <source>Proc Natl Acad Sci United States America</source> (<year>2003</year>) <volume>100</volume>(<issue>13</issue>):<page-range>7480&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/PNAS.1332608100/SUPPL_FILE/2608FIG5NEW.JPG</pub-id><pub-id pub-id-type="pmcid">PMC164612</pub-id><pub-id pub-id-type="pmid">12802011</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Predonzani</surname><given-names>A</given-names></name><name name-style="western"><surname>Arnoldi</surname><given-names>F</given-names></name><name name-style="western"><surname>L&#243;pez-Requena</surname><given-names>A</given-names></name><name name-style="western"><surname>Burrone</surname><given-names>OR</given-names></name></person-group>. <article-title>
<italic toggle="yes">In vivo</italic> site-specific biotinylation of proteins within the secretory pathway using a single vector system</article-title>. <source>BMC Biotechnol</source> (<year>2008</year>) <volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>11</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1472-6750-8-41/FIGURES/6</pub-id><pub-id pub-id-type="pmid">18423015</pub-id><pub-id pub-id-type="pmcid">PMC2373293</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fairhead</surname><given-names>M</given-names></name><name name-style="western"><surname>Howarth</surname><given-names>M</given-names></name></person-group>. <article-title>Site-specific biotinylation of purified proteins using bira</article-title>. <source>Methods Mol Biol (Clifton NJ)</source> (<year>2015</year>) <volume>1266</volume>:<fpage>171</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-1-4939-2272-7_12</pub-id><pub-id pub-id-type="pmcid">PMC4304673</pub-id><pub-id pub-id-type="pmid">25560075</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>A</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K</given-names></name></person-group>. <article-title>The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis</article-title>. <source>J Controlled Release</source> (<year>2017</year>) <volume>245</volume>:<fpage>27</fpage>&#8211;<lpage>40</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jconrel.2016.11.016</pub-id><pub-id pub-id-type="pmcid">PMC5222781</pub-id><pub-id pub-id-type="pmid">27865853</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chivers</surname><given-names>CE</given-names></name><name name-style="western"><surname>Crozat</surname><given-names>E</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C</given-names></name><name name-style="western"><surname>Moy</surname><given-names>VT</given-names></name><name name-style="western"><surname>Sherratt</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Howarth</surname><given-names>M</given-names></name></person-group>. <article-title>A streptavidin variant with slower biotin dissociation and increased mechanostability</article-title>. <source>Nat Methods</source> (<year>2010</year>) <volume>7</volume>(<issue>5</issue>):<page-range>391&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nmeth.1450</pub-id><pub-id pub-id-type="pmcid">PMC2862113</pub-id><pub-id pub-id-type="pmid">20383133</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perumal</surname><given-names>SK</given-names></name><name name-style="western"><surname>Raney</surname><given-names>KD</given-names></name><name name-style="western"><surname>Benkovic</surname><given-names>SJ</given-names></name></person-group>. <article-title>Analysis of the DNA translocation and unwinding activities of T4 phage helicases</article-title>. <source>Methods</source> (<year>2010</year>) <volume>51</volume>(<issue>3</issue>):<page-range>277&#8211;88</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ymeth.2010.02.011</pub-id><pub-id pub-id-type="pmcid">PMC2919206</pub-id><pub-id pub-id-type="pmid">20170733</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brune</surname><given-names>KD</given-names></name><name name-style="western"><surname>Howarth</surname><given-names>M</given-names></name></person-group>. <article-title>New routes and opportunities for modular construction of particulate vaccines: Stick, click, and glue</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>1432</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.01432</pub-id><pub-id pub-id-type="pmid">29997617</pub-id><pub-id pub-id-type="pmcid">PMC6028521</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zakeri</surname><given-names>B</given-names></name><name name-style="western"><surname>Fierer</surname><given-names>JO</given-names></name><name name-style="western"><surname>Celik</surname><given-names>E</given-names></name><name name-style="western"><surname>Chittock</surname><given-names>EC</given-names></name><name name-style="western"><surname>Schwarz-Linek</surname><given-names>U</given-names></name><name name-style="western"><surname>Moy</surname><given-names>VT</given-names></name><etal/></person-group>. <article-title>Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin</article-title>. <source>Proc Natl Acad Sci</source> (<year>2012</year>) <volume>109</volume>(<issue>12</issue>):<page-range>E690&#8211;E7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1115485109</pub-id><pub-id pub-id-type="pmcid">PMC3311370</pub-id><pub-id pub-id-type="pmid">22366317</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Pistolozzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Spy chemistry-enabled protein directional immobilization and protein purification</article-title>. <source>Biotechnol Bioengineering</source> (<year>2020</year>) <volume>117</volume>(<issue>10</issue>):<page-range>2923&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/BIT.27460</pub-id><pub-id pub-id-type="pmid">32543719</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>J</given-names></name><name name-style="western"><surname>Jia</surname><given-names>R</given-names></name><name name-style="western"><surname>Wenge</surname><given-names>D</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>One-step purification and immobilization of recombinant proteins using Spytag/Spycatcher chemistry</article-title>. <source>Biotechnol Lett</source> (<year>2021</year>) <volume>43</volume>(<issue>5</issue>):<page-range>1075&#8211;87</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/S10529-021-03098-X</pub-id><pub-id pub-id-type="pmid">33591462</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutherland</surname><given-names>AR</given-names></name><name name-style="western"><surname>Alam</surname><given-names>MK</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>CR</given-names></name></person-group>. <article-title>Post-translational assembly of protein parts into complex devices by using Spytag/Spycatcher protein ligase</article-title>. <source>ChemBioChem</source> (<year>2019</year>) <volume>20</volume>(<issue>3</issue>):<page-range>319&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/cbic.201800538</pub-id><pub-id pub-id-type="pmid">30358052</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>